Drug discovery starts with an overwhelming problem. There are billions of possible molecules, but only a tiny fraction will ever become real medicines. The challenge is not just finding molecules that bind to a target. It is finding the right molecules early enough, before time and capital are wasted downstream. This is the problem NOVA…
When decentralized artificial intelligence meets decentralized science, the result can be a completely new way of solving problems that have resisted progress for decades. NOVA, grounded on Bittensor’s Subnet 68 and created by Metanova Labs, is one of the clearest real world examples of what happens when these two sectors converge. It shows how open…
The Metanova Labs team, Micaela Bazo and Penn Apdr, discuss how their subnet is decentralizing drug discovery through AI-driven molecular screening. They explore upstream determinants of health, neuroplasticity, and strategic therapeutic targets like monoamine transporters and HDACs. The conversation also covers intellectual property in decentralized science, miner incentives, and the launch of NOVA Blueprint as…
